Abbott Diabetes Care received US Food and Drug Administration clearance for its FreeStyle Libre 3 continuous glucose monitor system, the company announced prior to market opening on 31 May.
The clearance lets Abbott sell the Libre 3 to patients aged four years and over and covers a 14-day lifespan...







